标题：Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis
作者：Zhang, Caiqing; Zhang, Shuisheng; Xu, Deguo; Liu, Rujun; Zhu, Qingshan; Zhao, Yi; Mao, Yantao; Tian, Yuan
作者机构：[Zhang, Caiqing] Shandong Univ, Dept Resp, Shandong Prov Qianfoshan Hosp, Jinan 250014, Shandong, Peoples R China.; [Zhang, Shuisheng] Peking Univ, 更多
通讯作者地址：[Tian, Y]Shandong Prov Qianfoshan Hosp, Dept Radiotherapy Oncol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
来源：CANCER MANAGEMENT AND RESEARCH
关键词：diarrhea; PD-1/PD-L1; NSCLC; meta-analysis
摘要：Purpose: We designed the study to illustrate the OR of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor-related diarrhea in patients with non-small cell lung cancer.; Method: This systematic review and meta-analysis were put into practice according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Incidence of all grades for PD-1/PD-L1 inhibitor-related diarrhea in NSCLC was taken into account.; Results: After screening and eligibility assessment of 57 articles, a total of 12 clinical trials involving 6,659 participants were collected for the final meta-analysis. The incidence risk of diarrhea for all grades was lower in PD-1 inhibitor monotherapy compared to monochemotherapy of docetaxel (OR=0.31, 95% CI [0.24, 0.41]; I-2=0%, Z=8.23 (p<0.00001)), while a similar result could also be seen in PD-L1 inhibitor monotherapy group (OR=0.41, 95% CI [0.27, 0.64]; I-2=59%, Z=3.92 [p<0.00001]). The opposite result can be seen when PD-1/PD-L1 inhibitor combined chemotherapy was compared to chemotherapy alone (OR=1.51, 95% CI [1.22, 1.87]; I-2=0%, Z=3.77 [p<0.00001]). Similar incidence trend could also be seen in the meta-analysis of diarrhea for grade 1-2 and grade 3-5.; Conclusion: The incidence risk of diarrhea associated with PD-1/-PD-L1 inhibitor monotherapy was significantly lower than that of docetaxel monotherapy group. However it was higher in PD-1/PD-L1 inhibitor combined with chemotherapy group compared with the chemotherapy alone group.